Clinical Research Directory
Browse clinical research sites, groups, and studies.
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
Sponsor: University of Miami
Summary
The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-02-09
Completion Date
2028-01-31
Last Updated
2026-03-05
Healthy Volunteers
No
Interventions
Durysta, Bimatoprost Intracameral Implant 10 µg
Participants in this arm will receive a one-time injection of Durysta (intracameral bimatoprost 10mcg). Participants will be followed by a total of 3 months.
Locations (1)
Bascom Palmer Eye Institute
Miami, Florida, United States